The frequency of cancer biomarkers detected in research studies differs from what is observed from testing in the clinic. Real-world data helps you better understand the actual numbers of patients with a particular cancer type and where and for which biomarkers are being tested.
Providing information on current molecular testing trends, QIAGEN RWI allows for an expanded view of cancer indications to be evaluated for your drug for maximum reach and success.
Knowing where cancer patients are being tested and for which biomarkers can help design more effective clinical trials and later market drugs as they are approved. With QIAGEN RWI, you can:
QIAGEN’s RWI portfolio combines robust real-world genomic data from over 200,000 cancer cases and advanced analytics to achieve better decisions faster in early drug and test development.
To access RWI, you can:
Do you have novel questions, hypotheses, and hurdles to overcome? Our team of scientists, bioinformaticists, and clinicians can help you strategize, customize, and deliver within your timeline.
Choose the best biomarkers and cancer indications for your molecularly targeted therapies
Identify appropriate patient cohorts and enhance your CDx design to improve stratification and success
Expand beyond the one biomarker, one drug paradigm with expert molecular profiling and drug-response analyses